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Background: Painful neuropathy is the most common and debilitating complication of diabetes and results in
hyperalgesia and allodynia. Hyperglycemia clearly plays a key role in the development and progression of diabetic
neuropathy. Current therapeutic approaches are only partially successful and they are only thought to reduce the pain
associated with peripheral neuropathy. Some natural products offer combined antioxidant, anti-inflammatory and
antinociceptive properties that may help to treat in a more integrative manner this condition. In this regard, the purpose
of this study was to investigate the antineuropathic effect of 7-hydroxy-3,4-dihydrocadalin in streptozotocin-induced
diabetic rats and mice without glucose control as well as the possible mechanism of action involved in this effect.
Methods: Rats and mice were injected with 50 or 200 mg/kg streptozotocin, respectively, to produce hyperglycemia. The
formalin test and von Frey filaments were used to assess the nociceptive activity. Rota-rod was utilized to measure motor
activity and malondialdehyde assay to determine anti-oxidative properties.
Results: After 3 weeks of diabetes induction, chemical hyperalgesia was observed in streptozotocin-injected rats.
Oral acute administration of 7-hydroxy-3,4-dihydrocadalin (0.3–30 mg/kg) decreased in a dose-dependent manner
formalin-evoked hyperalgesia in diabetic rats. In addition, methiothepin (non-selective 5-HT receptor antagonist, 1 mg/kg,
i.p.) and ODQ (guanylyl cyclase inhibitor, 2 mg/kg, i.p.), but not naltrexone (opioid receptor antagonist, 1 mg/kg, s.c.),
prevented 7-hydroxy-3,4-dihydrocadalin-induced antihyperalgesic effect. The anti-hyperalgesic effect of 7-hydroxy-3,
4-dihydrocadalin was similar to that produced by pregabalin (10 mg/kg, p.o.). Furthermore, oral acute administration of
7-hydroxy-3,4-dihydrocadalin (30 mg/kg) reduced streptozotocin-induced changes in malondialdehyde concentration
from plasma samples. Unlike pregabalin, 7-hydroxy-3,4-dihydrocadalin did not affect motor activity. Six weeks after
diabetes induction, tactile allodynia was observed in the streptozotocin-injected rats. At this time, oral administration of
7-hydroxy-3,4-dihydrocadalin (30 mg/kg) or pregabalin (10 mg/kg) reduced in a similar way tactile allodynia in diabetic
rats. Finally, chronic oral administration of 7-hydroxy-3,4-dihydrocadalin (30-300 mg/kg, 3 times/week, during 6 weeks),
significantly prevented the development of mechanical hyperalgesia and allodynia in streptozotocin-induced diabetic mice.
Conclusions: Data suggests that 7-hydroxy-3,4-dihydrocadalin has acute and chronic effects in painful diabetic
neuropathy. This effect seems to involve antioxidant properties as well as activation of 5-HT receptors and inhibition of
guanylyl cyclase enzyme.
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Diabetes mellitus is one of the most common chronic
medical conditions affecting over 366 million people
worldwide, causing 4.6 million deaths each year [1]. Dia-
betes leads to several complications including retinop-
athy, nephropathy and neuropathy. Diabetic neuropathy
is the most common and debilitating complication of
diabetes and results in pain, decreased motility, and leg
amputation. The prevalence of neuropathy is estimated
to be about 8% in newly diagnosed diabetic patients and
greater than 50% in patients with long-standing disease
[2,3]. Pain associated with diabetes can occur either
spontaneously or as a result of exposure to only mildly
painful stimuli (hyperalgesia) or to stimuli not normally
perceived as painful (allodynia) [4,5].
Diabetes occurs when the pancreas does not produce
enough insulin, or when the body cannot effectively use
the insulin produced. This leads to an increased concen-
tration of glucose in the blood. Hyperglycemia clearly
plays a key role in the development and progression of
diabetic neuropathy as it activates secondary glucose
metabolic pathways, such as the polyol and hexosamine
pathways; protein kinase C isoforms and advanced glyca-
tion end products. Collectively, these pathways cause an
imbalance in the mitochondrial redox state of the cell
leading to formation of reactive oxygen species that in
turn promote expression of genes involved in inflamma-
tion and neuronal dysfunction, for review see [3,6]. Al-
though, considerable progress has been made toward
understanding the mechanisms leading to diabetic neur-
opathy, the etiology of this condition is not fully under-
stood yet.
Current accepted therapeutic approaches are only par-
tially successful as they only decrease pain intensity
associated to this condition; however, they do not elim-
inate the root causes. In this regard, anticonvulsants, tri-
cyclic antidepressants and opioids have become the
mainstay in the treatment of diabetic neuropathic pain
[7,8]. However, these drugs have a limited effect or may
cause intolerable side-effects. Therefore, other options of
treatment are needed. An alternative is natural product-
derived compounds which represent a great structural
diversity. Some of these may offer combined antioxidant,
anti-inflammatory and antiallodynic properties, as well
as novel targets to treat neuropathic pain. Scientific evi-
dence shows that the antineuropathic effect of most of
natural products can be mainly explained by activation
of opioid, serotonergic and nitrergic systems [9-13], and
by antioxidant properties [14-16].
Heterotheca inuloides Cass (Asteraceae) or Mexican
arnica is a medicinal plant widely used in the Mexican
folk medicine to treat several painful conditions such as
wounds, bruises, rheumatisms, colic and other condi-
tions associated to visceral and somatic inflammatoryprocess [17]. Recent evidence obtained in our laboratory
points out that 7-hydroxy-3,4-dihydrocadalin seems to
be one of the main sesquiterpenoid responsible of the
antinociceptive effect of this plant in inflammatory
conditions [18]. Notwithstanding, considering that 7-
hydroxy-3,4-dihydrocadalin has antioxidant [19-21] and
anti-inflammatory [18,22] properties, the most import-
ant therapeutic effect of 7-hydroxy-3,4-dihydrocadalin
could be found it in the treatment of chronic pain, spe-
cially, in those painful conditions where there is an im-
balance of oxidative stress and systemic inflammatory
state as painful diabetic neuropathy.
Based on the above considerations, this work was
undertaken to investigate the effects of 7-hydroxy-3,4-
dihydrocadalin in streptozotocin-induced diabetic rats
and mice without blood glucose control as well as the
possible participation of opioid, serotonergic, nitrergic
and antioxidant systems in the generation of this effect.Methods
Animals
All experiments on acute treatment of 7-hydroxy-3,
4-dihydrocadalin were performed in adult male Wistar
rats weighting between 220 and 250 g, whereas expe-
riments on chronic treatment of 7-hydroxy-3,4-dihy-
drocadalin were carried out in male ICR mice ranging
between 28 and 30 g. Animals were obtained from
Centro UNAM-Harlan (Harlan México, S.A. de C.V.)
and they were fasted for 12-h before oral drug adminis-
tration. All experiments are in compliance with the
requirements published by SAGARPA in the Technical
Specifications for the Production, Care and Use of
Laboratory Animals (NOM-062-ZOO-1999), Guidelines
National Institute of Health Guide for the Care and Use
of Laboratory Animals (NIH Publications No. 80-23,
revised 1996) and Guidelines on Ethical Standards for
Investigation of Experimental Pain in Animals [23]. In
addition, the experiments were approved by Institu-
tional Committee for the Care and Use of Laboratory
Animals from Faculty of Chemistry (Protocol number
FQ/CICUAL/021/11). Every effort was done to mini-
mize pain and suffering in animals and the number of
rats used was the minimal required to obtain significant
statistical power.Plant material
Dried flowers of Heterotheca inuloides were kindly pro-
vided by Laboratorios Mixim S.A. de C.V. (Mexico City)
from its own growing fields in August 2010. Biologist
and M.Sc. Abigail Aguilar performed a formal identifi-
cation of the plant material and a voucher specimen was
deposited at the herbarium of the 21st Century National
Medical Center (Mexico City), with the number 15972.
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7-Hydroxy-3,4-dihydrocadalin was chosen as a candidate
for treatment of painful diabetic neuropathy from a bio-
assay guided fractionation previous study, on the basis
it was the main metabolite isolated from Heterotheca
inuloides with antinociceptive activity in inflammatory
pain models and as it combines antinociceptive, antioxi-
dative and anti-inflammatory properties. 7-Hydroxy-3,
4-dihydrocadalin was extracted from air-dried ground
inflorescences of Heterotheca inuloides (1500 g) as was
previously described by our laboratory group [18]. Briefly,
inflorescences were extracted three times for three days
each with 20 L of hexane by maceration at room
temperature (~ 22°C). After evaporation of solvent under
vaccum, 25 g hexane extract (1.67%) were obtained. Then,
7-hydroxy-3,4-dihydrocadalin was separated in a silica
chromatography column with hexane and purified by
recrystallization in hexane at 4°C. Purity (99.8%) of 7-
hydroxy-3,4-dihydrocadalin was confirmed by melting
point (103-104°C) [24] and Agilent 6890 N gas chromato-
graph with an automatic liquid sampler Agilent 7683B
coupled to a LECO Pegasus 4D mass spectrometer
(LECO, St. Joseph, MI, USA). Chemical structure of 7-
hydroxy-3,4-dihydrocadalin (Figure 1) was confirmed by
comparison of 1H- and 13C-nuclear magnetic resonances
data with those previously reported [25].
Drugs
7-Hydroxy-3,4-dihydrocadalin was prepared in deionized
water with 10% Tween 80. Methiothepin (1-[10,11
dihydro-8-(methylthio) dibenzo [b,f] thiepin-10-yl]-
4-methylpiperazine mesylate salt), pregabalin ((S)-3-
(aminomethyl)-5-methylhexanoic acid) and naltrexone
(naltrexone hydrochloride) were dissolved in 0.9% saline
solution, while ODQ (1H-[1,2,4] oxadiazolo[4,3-a]quino-
xalin-1-one) was prepared in 0.9% saline solution with
20% dimethylsulfoxide. Streptozotocin (N-(methylnitroso-
carbamoyl)-α-D-glucosamine) was dissolved in deionized
water. All drugs were freshly prepared before each experi-
ment and were purchased from Sigma-Aldrich (St. Louis,
MO, USA), with exception of 7-hydroxy-3,4-dihydrocada-
lin, which was extracted from dried flowers of Heterotheca
inuloides.Figure 1 Chemical structure of 7-hydroxy-3,4-dihydrocadalin.Induction of experimental diabetes by streptozotocin
Rats or mice were intraperitoneally injected with 50 or
200 mg/kg of streptozotocin, respectively, to produce ex-
perimental diabetes [26,27]. Control animals (weight-
matched) received saline 0.9%. Diabetes was confirmed
one day after streptozotocin injection and 12 h before
acute experiments by measurement of tail vein blood
glucose levels with a glucometer OneTouch® UltraMini™
(LifeScan Inc., Milpitas, CA, USA). Only rats with a
blood glucose level ≥ 350 mg/dL were included in the
study. For chronic experiments in mice, glucose levels
were monitored each week during six weeks and all mice
maintained more than 350 mg/dL of glucose throughout
the experiment.
Measurement of hyperalgesia in rats
To determine the antihyperalgesic role of 7-hydroxy-3,4-
dihydrocadalin, the formalin test was performed as de-
scribed elsewhere [28]. Streptozotocin-induced diabetic rats
(after 3 weeks) were placed in open observation chambers
for 30 min to allow them to acclimate to their surround-
ings; then they were removed and gently restrained while
the dorsum of the hind paw was injected with 50 μL of
0.5% formalin using a 30-gauge needle. The animals were
returned to the chambers and the nociceptive behavior was
observed immediately after formalin injection. Mirrors were
placed in each chamber to enable unhindered observation.
Nociceptive behavior was quantified as the number of
flinches of the injected paw during 1-min periods every 5
min, up to 60 min after formalin injection [29]. Flinching
was readily discriminated and was characterized as rapid
and brief withdrawal, or as flexing of the injected paw. At
the end of the experiments, rats were sacrificed in a CO2
chamber.
Measurement of allodynia in rats
Tactile allodynia was tested in rats with 6 weeks of
streptozotocin-induced experimental diabetes as previ-
ously described [30]. Briefly, rats were transferred to a
clear plastic, wire mesh-bottomed cages and allowed to
acclimatize for 30 min. von Frey filaments (Stoelting,
WoodDale, IL, USA) were used to determine the 50%
paw withdrawal threshold using the up–down method
[31]. A series of filaments, starting with one that had a
buckling weight of 2 g, were applied in consecutive se-
quence to the plantar surface of the right hind paw with
a pressure causing the filament to buckle during 5 sec-
onds. Lifting of the paw before of 5 seconds indicated a
positive response and prompted the use of the next
weaker filament whereas that absence of a paw with-
drawal after 5 seconds indicated a negative response and
prompted the use of the next filament of increasing
weight. This paradigm continued until four more mea-
surements had been made after the initial change of the
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(assigned a score of 15 g) or four consecutive positive
(assigned a score of 0.25 g) responses had occurred. The
resulting scores were used to calculate 50% of with-
drawal threshold, by using the formula:
50% g threshold ¼ 10
Xf þ κδð Þ
10 000
where Xf = the value (in log units) of the final von Frey
filament used, κ = the value from table for the pattern of
positive and negative responses published previously
[32], and ∂ = the mean difference (in log units) between
stimuli. 50% threshold withdrawal was assessed before
drug administration and every 60 min during 8 h and at
24 h after drug administration. Allodynia was considered
to be present when paw withdrawal threshold was below
4 g as was described above [32]. Diabetic rats with a
basal withdrawal threshold above 4 g were not included
for the experiments.
Measurement of hyperalgesia and allodynia in mice
Secondary mechanical allodynia and hyperalgesia in
streptozotocin-induced diabetic mice were assessed by a
modified method described above [33,34]. Mice were
placed in testing cages with a wire mesh bottom and
allowed to acclimate for 30 min. Baseline measurements
were recorded first. Two von Frey filaments (Stoelting
Co, Wood Dale, IL, USA; bending forces of 0.008 g
[1.65] and 1 g [4.08]) were applied 10 times in each test-
ing set at the base of the third toe on the plantar surface
on right hindpaw. Three trials were completed to get an
average of the number of paw withdrawal responses.
Under normal conditions, a force of 0.008 g does not ac-
tivate cutaneous nociceptors, and therefore, it does not
cause paw withdrawal in normal mice. Accordingly, the
occurrence of responses in diabetic mice indicates allo-
dynia. On the other hand, a force of 1 g or more is con-
sidered a noxious stimulus, and hyperalgesia occurs
when there is an increased response to this stimulus.
Measurement of malondialdehyde
Determination of malondialdehyde concentration in
streptozotocin-induced diabetic rat plasma (3 weeks)
was carried out according to the manufacturer´s instruc-
tions (Cayman Chemical Company, Ann Arbor, MI,
USA). Concisely, 3 mL of blood were obtained from
femoral vein of anesthetized rats in heparinized tubes;
blood was centrifuged at 1000 × g for 10 min at 4°C.
Then, plasma (100 μL) was mixed with SDS (100 μL)
and 4 mL of color reagent in 5-mL tubes. Mixture was
boiled during 1 h and placed in an ice bath for 10 min
to stop reaction. After that, tubes were centrifuged at 1
600 × g during 10 min at 4°C and read at 540 nm. Thecalibration curve was linear from 5 to 400 μM malon-
dialdehyde (r2 = 0.998).Evaluation of motor activity
Motor activity was assessed using a rota-rod apparatus
for rats (Panlab 8500, Cornellá, BCN, Spain) as was de-
scribed above [35]. Diabetic rats (3 weeks) were trained
for 2 days by walking them each day on an accelerating
rota-rod (from 4 to 40 r.p.m. in 10 min). On the test
day, trained animals were tested 1 h after drug adminis-
tration (time of peak drug effect). Motor performance
was considered as the latency to fall off the rota-rod ap-
paratus determined from the mean time in three trials
for each rat at each time.Study design
Independent groups of animals (n = 5-7) were used for each
experimental condition. In order to define the best time to
administer 7-hydroxy-3,4-dihydrocadalin, diabetic rats (3
weeks) received an oral administration of vehicle (saline so-
lution with 10% tween 80) or 7-hydroxy-3,4-dihydrocadalin
(30 mg/kg, p.o.) at 30 and 60 min before formalin injection
(50 μL). These times were selected from pilot experiments
in our laboratory. Since the best antinociceptive effect was
observed at the 60 min pre-treatment (data not shown),
dose–response curve to assess the acute antihyperalgesic ef-
fect of 7-hydroxy-3,4-dihydrocadalin was carried out giving
vehicle or increasing doses of 7-hydroxy-3,4-dihydrocadalin
(0.03 – 30 mg/kg) or a single dose (10 mg/kg) of pregabalin
(positive control) 60 min before subcutaneous injection (50
μL) of 1% formalin into the dorsal surface of the right hind-
paw. In order to establish the potential participation of
guanylyl cyclase enzyme or serotonin and opioid receptors
on 7-hydroxy-3,4-dihydrocadalin-induced systemic antihy-
peralgesic effect, ODQ (2 mg/kg), methiothepin (1 mg/kg)
or naltrexone (1 mg/kg) were administered 30 min after a
single dose of 7-hydroxy-3,4-dihydrocadalin (30 mg/kg)
and 30 min before 1% formalin injection. To corroborate
the lack of effect of ODQ, methiothepin and naltrexone by
themselves at the tested dose with 7-hydroxy-3,4-dihydro-
cadalin, they were administered alone 30 min before 1%
formalin injection into the right paw.
In an attempt to determine the antioxidant properties of
7-hydroxy-3,4-dihydrocadalin in streptozotocin-induced di-
abetic rats, the malondialdehyde concentration was mea-
sured in plasma samples of naïve and diabetic (3 weeks)
rats treated with vehicle or 7-hydroxy-3,4-dihydrocadalin
(30 mg/kg) 60 min before taking a blood sample from the
femoral vein. In order to evaluate the effect of 7-hydroxy-
3,4-dihydrocadalin (30 mg/kg) and pregabalin (10 mg/kg)
on motor activity, diabetic rats (3 weeks) were orally
administered with vehicle (saline solution with 10% tween
80) or a single dose of 7-hydroxy-3,4-dihydrocadalin or
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in a rota-rod apparatus.
To confirm the acute antineuropathic effect of 7-
hydroxy-3,4-dihydrocadalin, naïve and streptozotocin-
induced diabetic rats of 6 weeks were administered with
vehicle or the highest dose tested of 7-hydroxy-3,4-dihy-
drocadalin (30 mg/kg) or pregabalin (10 mg/kg) in the
formalin test. After oral administration, antiallodynic ef-
fect of treatments was evaluated by von Frey filaments
measuring 50% paw mechanical withdrawal threshold
during 24 h [31]. Finally, in order to establish whether
7-hydroxy-3,4-dihydrocadalin was able to delay the
development of streptozotocin-induced diabetic neur-
opathy, naïve or diabetic mice were orally treated with
vehicle or increasing doses of 7-hydroxy-3,4-dihydroca-
dalin (30 – 300 mg/kg) on Mondays, Wednesdays and
Fridays of each week during 6 weeks. In this paradigm,
hyperalgesia and allodynia were measured all Mondays
before drug administration as the number of hind paw
withdrawal responses at 0.008 g and 1 g, respectively.
The scheduling of doses and drug administration was
based on previously reported studies [36,37] and on pilot
studies in our models. The observer was unaware of the
treatment given to each animal. Rats in all groups were
tested for possible side effects such as reduction of righ-
ting, stepping, and corneal and pinna reflexes, before
and after drug treatment, as proposed elsewhere [38].
Data analysis and statistics
Results of malondialdehyde concentration and motor ac-
tivity are presented in bar plots as means ± S.E.M. for at
least five animals per group, whereas bar graphs of noci-
ceptive experiments were made of the area under the
curve from time courses by the trapezoidal rule as was
previously described [39]. Time courses were con-
structed by plotting the number of flinches (hyperalgesia
in rats) or paw withdrawal threshold in grams (allodynia
in rats) or the number of paw withdrawal responses
(hyperalgesia and allodynia in mice) as a function of
time. All nociception results are presented as means ±
S.E.M. for 5-7 animals per group. One-way analysis of
variance (ANOVA) followed by the Tukey’s test was used
to compare differences between treatments. In addition,
two-way ANOVA followed by the Bonferroni´s test was
carried out to compare differences between treatments
in a time course. Differences were considered statisti-
cally significant when P < 0.05.
Results
Formalin-evoked flinching behavior in streptozotocin-
induced diabetic rats Streptozotocin, but not distilled
water, injection in non-fasted rats caused hyperglycemia.
The blood glucose level measured in these rats was
116.6 ± 2.1 mg/dL and 112.5 ± 3.0 mg/dL before distilledwater or streptozotocin injection, and 116.4 ± 1.7 mg/dL
and 559.5 ± 9.6 mg/dL 3 weeks after distilled water or
streptozotocin injection, respectively. Furthermore, dia-
betic rats had an increase in food and water intake,
showed polyuria and did not gain body weight (data not
shown). Both the non-diabetic and diabetic (3 weeks)
groups exposed to subcutaneous injection of 0.5% for-
malin exhibited a biphasic pattern of flinching. Phase 1
of the nociceptive response began immediately after for-
malin administration and then declined gradually in ap-
proximately 10 min. Phase 2 began about 15 min after
formalin administration and lasted about 1 h, as previ-
ously reported [29]. Injection of 0.5% formalin into the
right paw displayed a greater flinching behavior in dia-
betic compared to non-diabetic rats (Figure 2A). Actu-
ally, analysis of formalin-evoked nociceptive behavior as
area under curve (AUC) showed that increment in the
flinching frequency of diabetic rats was statistically dif-
ferent (P < 0.05) compared to non-diabetic rats in both
phases of the test (Figure 2B,C).
Antihyperalgesic effect of acute administration of
7-hydroxy-3,4-dihydrocadalin in diabetic rats
Oral administration of 7-hydroxy-3,4-dihydrocadalin (30
mg/kg) reduced formalin-induced flinching behavior at 30
and 60 min pre-treatment. However, the best antinocicep-
tive effect was observed at 60 min pre-treatment (data not
shown) and this pre-treatment time was used in the follow-
ing experiments. Under this condition, 7-hydroxy-3,4-dihy-
drocadalin decreased in a dose-dependent manner and
significantly (P < 0.05) the number of flinches during both
phases of the formalin test in diabetic rats (Figure 3A,B). In
addition, 7-hydroxy-3,4-dihydrocadalin (30 mg/kg) showed
to be equi-effective in percentage of antinociception to
pregabalin (10 mg/kg) during phase 1 (55.9 ± 11.4% and
49.1 ± 9.9%, respectively) and phase 2 (70.0 ± 5.2% and
65.7 ± 2.7%, respectively) of the formalin test. Higher doses
of pregabalin were not compared with 7-hydroxy-3,4-dihy-
drocadalin due to the fact that pregabalin showed evident
motor side-effects that affected flinching behavior.
Effect of methiothepin, naltrexone and ODQ on the
antihyperalgesic effect of 7-hydroxy-3,4-dihydrocadalin in
diabetic rats
In order to assess the participation of 5-HT and opioid
receptors as well as guanylyl cyclase enzyme on 7-hydroxy-
3,4-dihydrocadalin-induced antihyperalgesic effect in the
1% formalin test, methiothepin (non-selective 5-HT recep-
tor antagonist), naltrexone (non-selective opioid receptor
antagonist) or ODQ (selective guanylyl cyclase inhibitor)
were injected 30 min after oral administration of 7-
hydroxy-3,4-dihydrocadalin. Figure 4 shows that subcuta-
neous administration of 1 mg/kg naltrexone (Figure 4A,B)
was not able to block 7-hydroxy-3,4-dihydrocadalin-
Figure 2 Flinching behavior induced by subcutaneous (s.c.)
injection of 0.5% formalin to non-diabetic and diabetic rats. Time
courses (A) and bar plots show formalin-induced hyperalgesic effect
during phase 1 (B) and phase 2 (C) in diabetic rats administered with 60
mg/kg (i.p.) of streptozotocin 3 weeks before. Data are expressed as the
mean ± E.E.M. of seven animals per group. *Significantly different
(P< 0.05) from non-diabetic group, as determined by Student’s test. AUC:
area under the curve.
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test (Figure 4A,B). In marked contrast, intraperitoneal
administration of 1 mg/kg methiothepin (Figure 4C,D) or 2
mg/kg ODQ (Figure 4E,F) significantly prevented the
antihyperalgesic effect of 7-hydroxy-3,4-dihydrocadalin
in both phases of this test. The doses of naltrexone,
methiothepin or ODQ did not modify per se formalin-
induced nociceptive behavior and such doses were chosen
on the basis of previously results obtained in the laboratory
and in the literature [36,37].Antioxidative effect of acute administration of 7-hydroxy-
3,4-dihydrocadalin in diabetic rats
Three weeks after streptozotocin, but not distilled water,
a significant increase of malondialdehyde concentration
was observed in plasma samples. This increase was
markedly (P < 0.05) reduced by oral acute treatment of
7-hydroxy-3,4-dihydrocadalin (30 mg/kg, -60 min) (Fig-
ure 5). In addition, 7-hydroxy-3,4-dihydrocadalin did not
significantly modify serum malondialdehyde concentra-
tion in non-diabetic rats (data not shown).Effect of acute administration of 7-hydroxy-3,
4-dihydrocadalin on motor activity of diabetic rats
To determine motor side-effects of acute oral adminis-
tration (-60 min) of vehicle or equieffective doses of
7-hydroxy-3,4-dihydrocadalin (30 mg/kg) and pregabalin
(10 mg/kg) in diabetic rats (3 weeks) was performed the
rota-rod test. Under these conditions, pregabalin, but
not 7-hydroxy-3,4-dihydrocadalin, significantly (P < 0.05)
reduced motor activity of streptozotocin-induced dia-
betic rats compared to vehicle group (Figure 6).Antiallodynic effect of acute administration of 7-hydroxy-
3,4-dihydrocadalin in diabetic rats
In order to confirm the antineuropathic effect of 7-
hydroxy-3,4-dihydrocadalin, streptozotocin-diabetic rats
were evaluated with the von Frey filaments. Hypergly-
cemic rats developed tactile allodynia around 6 weeks
after streptozotocin injection. In marked contrast, non-
diabetic animals remained with a normal threshold
during the 6 weeks. No autotomy behavior was ever
observed during the experiment. On this condition, oral
acute administration of 7-hydroxy-3,4-dihydrocadalin
(30 mg/kg) or pregabalin (10 mg/kg), but not vehicle,
increased the withdrawal threshold in diabetic rats. Both
drugs reached the maximal antiallodynic effect at 2 h
and it lasted for 8 h at the tested doses, 24 h after oral
administration the antiallodynic effect had disappeared
(Figure 7). In a similar way to the formalin test,
7-hydroxy-3,4-dihydrocadalin (69.9 ± 4.0%) was equi-
effective to pregabalin (67.8 ± 4.1%) in this model.
Figure 3 Antihyperalgesic effect induced by oral administration of increasing doses of 7-hydroxy-3,4-dihydrocadalin (7-DHC) or 10
mg/kg pregabalin (PGB) in diabetic rats (3 weeks) during phase 1 (A) and phase 2 (B) of the 0.5% formalin test. 7-DHC and PGB were
given 1 h before formalin injection. Data are expressed as the mean ± E.E.M. of six animals per experimental group. *Significantly different
(P < 0.05) from the control group (diabetic), as determined by analysis of variance followed by Tukey´s test. AUC: Area under the curve.
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administration of 7-hydroxy-3,4-dihydrocadalin in diabetic
mice
Streptozotocin (200 mg/kg), but not distilled water (0.1
mL/kg), injection caused hyperglycemia in mice. The
ICR mice had 120.7 ± 9.4 and 126.6 ± 10.6 mg/dL of fed
blood glucose levels before distilled water or streptozo-
tocin injection, and 121.2 ± 6.5 and 551.2 ± 13.8 mg/dL 6
weeks after distilled water or streptozotocin injection,
respectively. Furthermore, diabetic mice had an increase
in mechanical hyperalgesia and allodynia from the first
week compared to vehicle group. Oral administration of
7-hydroxy-3,4-dihydrocadalin, but not vehicle, on Mon-
days, Wednesday and Fridays during 6 weeks prevented
in a dose-dependent manner (30–300 mg/kg) and sig-
nificantly (P < 0.05) the development of mechanical
hyperalgesia and allodynia in diabetic mice (Figure 8).
Evaluations were done weekly (on Mondays), 72 h after
the last oral administration of 7-hydroxy-3,4-dihydroca-
dalin or vehicle in these animals.
Discussion
The current study was performed to determine the
therapeutic potential of 7-hydroxy-3,4-dihydrocadalin in
the treatment of streptozotocin-induced painful periph-
eral neuropathy in rodents. In our study, dose-response
curve of 7-hydroxy-3,4-dihydrocadalin acute administra-
tion presented a dose-dependent antihyperalgesic effect
in the formalin test in diabetic rats. In addition, this
drug showed antiallodynic activity in the streptozotocin-
induced tactile allodynia model. In both tests, the anti-
neuropathic effect was equieffective to pregabalin, a drug
of first line in the treatment of neuropathic pain [40,41].
In line with these results, chronic administration of oral
7-hydroxy-3,4-dihydrocadalin also prevented the devel-
opment of mechanical hyperalgesia and allodynia in
mice. In contrast with the doses used in rats, the anti-
neuropathic activity was observed in mice with doses of7-hydroxy-3,4-dihydrocadalin 10 times greater. Differ-
ences could be attributed to the specie used (rats versus
mice) since it is well known that hepatic metabolism of
mice is more accelerated than rats [42-44]. To the best of
our knowledge, this is the first report about the antineuro-
pathic activity of 7-hydroxy-3,4-dihydrocadalin. Our study
agree with a previous study showing the antinociceptive ef-
fect of 7-hydroxy-3,4-dihydrocadalin in non-diabetic rats
submitted to 1% formalin test and Randall-Selitto model
[18]. Taken together, data suggest that 7-hydroxy-3,4-dihy-
drocadalin exerts antinociceptive activity in neuropathic
and inflammatory pain models. In addition, results seem to
point out that 7-hydroxy-3,4-dihydrocadalin has an advan-
tage on the rest of antineuropathic drugs used in the clinic
to treat painful diabetic neuropathy as this compound not
only reduces neuropathic pain intensity, but also prevents
the development of this condition. In this regard, results
indicate that 7-hydroxy-3,4-dihydrocadalin produced its
antinociceptive effect by a glucose levels-independent
mechanism as this compound was not able to modify blood
glucose in an acute or chronic administration schedule.
The mechanism of the antinociceptive effect of 7-
hydroxy-3,4-dihydrocadalin in neuropathic diabetic rats is
unknown. However, considering that opioid, serotonergic
and nitrergic systems are the most promising targets for
the treatment of peripheral diabetic neuropathy or neuro-
pathic pain by natural products [9-13], and it has been
reported that 7-hydroxy-3,4-dihydrocadalin activates 5-
HT1, but not opioid receptors [18], we decided to test if
these mechanisms participated in the antineuropathic
activity of 7-hydroxy-3,4-dihydrocadalin in diabetic rats.
In this regard, we found that the non-selective 5-HT recep-
tor antagonist methiothepin [45] was able to prevent
7-hydroxy-3,4-dihydrocadalin-induced antihyperalgesia in
three-week diabetic rats. This result suggests that some of
the 5-HT receptors may play a role in the antihyperalgesic
effect of 7-hydroxy-3,4-dihydrocadalin in streptozotocin-
induced diabetic rats. In support of this, there is evidence
Figure 4 Effect of systemic s.c. naltrexone (NTX, opioid antagonist, A-B), i.p. methiothepin (MET, 5-HT antagonist, C-D), and i.p. 1H-
[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, guanylyl cyclase inhibitor, E-F) on p.o. 7-hydroxy-3,4-dihydrocadalin-induced (7-DHC)
antihyperalgesic effect during both phases of 0.5% formalin test in diabetic rats (3 weeks). 7-DHC was given 1 h before formalin injection
whereas antagonists or inhibitor were given 30 min after oral 7-DHC administration. Antagonists or inhibitor did not show any nociceptive effect
by themselves at the tested dose for its administration with 7-DHC. Data are expressed in bars as average of the area under the curve (AUC) ±
E.E.M. of six animals per group. *Significantly different (P < 0.05) from control group (diabetic) and #significantly different (P < 0.05) from 7-DHC
group (30 mg/kg), as determined by one-way ANOVA followed by the Tukey’s test. AUC: Area under the curve; n.s.: not significant.
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http://www.biomedcentral.com/1472-6882/14/129that activation of 5-HT1A/B/D receptors participate in the
peripheral antinociceptive effect observed with 7-hydroxy-
3,4-dihydrocadalin in formalin-induced inflammatory pain
[18]. The participation of 5-HT1A seems unlikely because
the most of literature points out a pronociceptive role of 5-
HT1A receptor in several models of neuropathic pain
[46-48] including thermal hyperalgesia in streptozotocin-induced diabetic mice [49], notwithstanding, this has been
disputed [50,51]. On the other hand, evidence of 5-HT1B/D
receptors in neuropathic pain suggests that they are linked
to antinociception [52] and could explain the antihyperalge-
sic effect of 7-hydroxy-3,4-dihydrocadalin.
In the current study we also found that ODQ prevented
7-hydroxy-3,4-dihydrocadalin -induced antihyperalgesic
Figure 5 Effect of acute (30 mg/kg) oral administration of
7-hydroxy-3,4-dihydrocadalin (7-DHC) on malondialdehyde
concentration in plasma of diabetic rats submitted to 60 mg/kg
streptozotocin 3 weeks before. 7-DHC was given 1 h before blood
sampling. Bars are the mean ± E.E.M. for 5 animals. *Significantly
different from the non-diabetic group and #significantly different
(P < 0.05) from its respective control group (diabetic), as determined
by one-way ANOVA followed by the Tukey’s test.
Figure 7 Time course of the antiallodynic effect observed after
acute oral of 30 mg/kg 7-hydroxy-3,4-dihydriocadalin (7-DHC) or
10 mg/kg pregabalin (PGB) administration in rats administered
with 60 mg/kg streptozotocin (STZ) 6 weeks before experiment.
The non-diabetic group is placed as a reference of the maximum
possible effect, whereas diabetic group shows that antiallodynic effect is
induced by 7-DHC or PGB, but not by vehicle. Data are presented as
mean ± E.E.M. for 6 animals. Both treatments were significantly different
(P< 0.05) from control group (diabetic) in the range of 1 to 8 h, as was
determined by two-way ANOVA followed by Bonferroni’s test, but
asterisks were removed for the sake of clarity.
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inhibitor [53], our data suggest that antihyperalgesia ob-
served with 7-hydroxy-3,4-dihydrocadalin in diabetic rats
could be due to activation of guanylyl cyclase. Hypothe-
sizing, this activation would lead to the synthesis of cyclic
GMP, which in turn, would activate the protein kinase G
and finally it could open potassium channels to hyperpo-
larize the nociceptive neurons, as with the natural pro-
ducts that activate this enzyme [12,13].
On marked contrast, subcutaneous administration of the
non-selective opioid receptor antagonist naltrexone did not
prevent the antihyperalagesic effect induced by the acuteFigure 6 Effect of oral acute 30 mg/Kg 7-hydroxy-3,4-
dihydrocadalin (7-DHC) or 10 mg/kg pregabalin (PGB)
administration on motor coordination of diabetic rats submitted
to 60 mg/kg streptozotocin 3 weeks before. 7-DHC and PGB
were given 1 h before motor coordination testing. Bars are the
mean ± E.E.M. for 5 animals. *Significantly different (P < 0.05) from
control group (diabetic), as determined by one-way ANOVA
followed by the Tukey’s test.administration of 7-hydroxy-3,4-dihydrocadalin. This result
indicates that opioid receptors do not play a role in the
antihyperalgesic effect of 7-hydroxy-3,4-dihydrocadalin in
streptozotocin-induced diabetic rats of 3 weeks. The lack of
effect of naltrexone is not due to the dose used in this work,
since this dose has been reported to be effective in previous
studies in diabetic rats with similar characteristics [30,54].
Taken together, results suggest that 7-hydroxy-3,4-dihydro-
cadalin exerts its antihyperalgesic affect through activation
of 5-HT1 receptors and guanylyl cyclase enzyme, but not
opioid receptors.
Additionally to the described mechanisms, 7-hy-
droxy-3,4-dihydrocadalin decreased the malondialdehyde
concentration in diabetic rats to baseline values in
non-diabetic rats. Our data agree with evidence demon-
strating a potent scavenging activity of 7-hydroxy-3,4-
dihydrocadalin on diphenyl-p-picrylhydrazyl radical or
microsomal and mitocondrial lipid peroxidation [19-21].
Furthermore, 7-hydroxy-3,4-dihydrocadalin has shown
to be effective to protect red cells against oxidative
haemolysis [20] or mitochondrial enzyme activity against
oxidative stress [21]. Antioxidant activity of 7-hydroxy-
3,4-dihydrocadalin results of interest as pathogenesis of
Figure 8 Antineuropathic effect of chronic oral administration of 30 or 300 mg/kg of 7-hydroxy-3,4-dihydrocadalin (7-DHC), on Monday,
Wednesday and Friday for 6 weeks, on 200 mg/kg streptozotocin-induced hyperalgesia and allodynia in diabetic mice. Data are presented
as mean ± E.E.M. for 6 animals. *Significantly different (P < 0.05) from control group (diabetic), as was determined by two-way ANOVA followed by
Bonferroni’s test.
Rocha-González et al. BMC Complementary and Alternative Medicine 2014, 14:129 Page 10 of 12
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several pathways that interact in a mutually facilitatory
fashion to cause an imbalance in the mitochondrial redox
state and an increment in the expression of pro-
inflammatory genes producing neuronal hypersensitivity
[3,5]. Remarkably, 7-hydroxy-3,4-dihydrocadalin has also
demonstrated anti-inflammatory properties on the croton
oil-induced edema test in mouse ear [22] and carrageenan-
induced paw edema model [18]. Speculating, 7-hydroxy-
3,4-dihydrocadalin could be useful to treat the diabetic
neuropathy in a more integrative manner as it combines
antineuropathic, antioxidant and possibly anti-inflamma-
tory properties.
Although pregabalin is clinically considered as the
gold standard for the treatment of painful diabetic
neuropathy in human beings [55], its use is limited
due to side effects such as sedation, dizziness and
somnolence that affects motor coordination [56,57].
For this reason, equi-effective doses of 7-hydroxy-3,4-
dihydrocadalin and pregabalin were compared in the
rota-rod test. Interestingly, pregabalin, but not 7-
hydroxy-3,4-dihydrocadalin, affected motor coordin-
ation in diabetic rats. Our results seem to point out
that notwithstanding the similar antineuropathic acti-
vity between both drugs, 7-hydroxy-3,4-dihydrocadalin
might present an advantage on pregabalin in the
diabetic neuropathy treatment since 7-hydroxy-3,4-
dihydrocadalin did not produce motor side-effects.
However, further studies are necessary to assess the
safety of oral acute and chronic administration of
7-hydroxy-3,4-dihydrocadalin. In addition, a clinical
study of efficacy and safety study in patients with
painful diabetic neuropathy is required to evaluate the
real therapeutic potential of this compound in the
diabetic neuropathy.Conclusions
Data suggest that 7-hydroxy-3,4-dihydrocadalin, an active
compound of Mexican arnica with antioxidant, anti-
inflammatory and antinociceptive activities, has therapeutic
potential for diabetic neuropathy treatment, since oral ad-
ministration of this compound decreased hyperalgesia and
allodynia in a similar way than pregabalin in rats without
affecting motor coordination. In addition, this drug may be
useful to prevent the development of painful diabetic neur-
opathy as its chronic administration avoided the progress
of neuropathic pain in mice. The antinociceptive effect
seems to involve activation of 5-HT1 receptors and guanylyl
cyclase enzyme, whereas its neuroprotective mechanisms
could be more related to the antioxidant properties of 7-
hydroxy-3,4-dihydrocadalin.
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